These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 21455855)

  • 1. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
    Zamagni E; Brioli A; Tacchetti P; Zannetti B; Pantani L; Cavo M
    Semin Thromb Hemost; 2011 Apr; 37(3):209-19. PubMed ID: 21455855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
    Palumbo A; Rajkumar SV; Dimopoulos MA; Richardson PG; San Miguel J; Barlogie B; Harousseau J; Zonder JA; Cavo M; Zangari M; Attal M; Belch A; Knop S; Joshua D; Sezer O; Ludwig H; Vesole D; Bladé J; Kyle R; Westin J; Weber D; Bringhen S; Niesvizky R; Waage A; von Lilienfeld-Toal M; Lonial S; Morgan GJ; Orlowski RZ; Shimizu K; Anderson KC; Boccadoro M; Durie BG; Sonneveld P; Hussein MA;
    Leukemia; 2008 Feb; 22(2):414-23. PubMed ID: 18094721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
    Cini M; Zamagni E; Valdré L; Palareti G; Patriarca F; Tacchetti P; Legnani C; Catalano L; Masini L; Tosi P; Gozzetti A; Cavo M
    Eur J Haematol; 2010 Jun; 84(6):484-92. PubMed ID: 20192986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
    Musallam KM; Dahdaleh FS; Shamseddine AI; Taher AT
    Thromb Res; 2009 Mar; 123(5):679-86. PubMed ID: 18992924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.
    Anaissie EJ; Coleman EA; Goodwin JA; Kennedy RL; Lockhart KD; Stewart CB; Coon SK; Bailey C; Barlogie B
    Cancer; 2012 Jan; 118(2):549-57. PubMed ID: 21720994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin.
    Kato A; Takano H; Ichikawa A; Koshino M; Igarashi A; Hattori K; Nagata K
    Thromb Res; 2013 Feb; 131(2):140-4. PubMed ID: 23232090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.
    Hussein MA
    Thromb Haemost; 2006 Jun; 95(6):924-30. PubMed ID: 16732369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.
    Uaprasert N; Voorhees PM; Mackman N; Key NS
    Eur J Cancer; 2010 Jul; 46(10):1790-9. PubMed ID: 20385482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
    Klein U; Kosely F; Hillengass J; Hundemer M; Schmitt S; Neben K; Moehler T; Hegenbart U; Ho AD; Goldschmidt H
    Ann Hematol; 2009 Jan; 88(1):67-71. PubMed ID: 18668241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombosis in multiple myeloma.
    Zangari M; Elice F; Fink L; Tricot G
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):307-15. PubMed ID: 17338651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
    Zangari M; Fink L; Zhan F; Tricot G
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of treatment-related adverse events in patients with multiple myeloma.
    Mateos MV
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S24-32. PubMed ID: 20472185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs.
    Leleu X; Rodon P; Hulin C; Daley L; Dauriac C; Hacini M; Decaux O; Eisemann JC; Fitoussi O; Lioure B; Voillat L; Slama B; Al Jijakli A; Benramdane R; Chaleteix C; Costello R; Thyss A; Mathiot C; Boyle E; Maloisel F; Stoppa AM; Kolb B; Michallet M; Lamblin A; Natta P; Facon T; Elalamy I; Fermand JP; Moreau P
    Thromb Haemost; 2013 Oct; 110(4):844-51. PubMed ID: 23903204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide and thrombosis. A meta-analysis.
    El Accaoui RN; Shamseddeen WA; Taher AT
    Thromb Haemost; 2007 Jun; 97(6):1031-6. PubMed ID: 17549307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.
    Wu SY; Yeh YM; Chen YP; Su WC; Chen TY
    Ann Hematol; 2012 Nov; 91(11):1773-8. PubMed ID: 22706703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
    Al-Ani F; Bermejo JM; Mateos MV; Louzada M
    Thromb Res; 2016 May; 141():84-90. PubMed ID: 26986753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update of thrombosis in multiple myeloma.
    Leebeek FW
    Thromb Res; 2016 Apr; 140 Suppl 1():S76-80. PubMed ID: 27067983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.
    Alexander M; Teoh KC; Lingaratnam S; Kirsa S; Mellor JD
    Asia Pac J Clin Oncol; 2013 Jun; 9(2):169-75. PubMed ID: 22998589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials.
    Thaler J; Ay C; Pabinger I
    Thromb Haemost; 2012 Dec; 108(6):1042-8. PubMed ID: 22836491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients.
    Cohen AT; Nandini B; Wills JO; Ota S
    Thromb Res; 2010 Apr; 125 Suppl 2():S21-9. PubMed ID: 20434000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.